Sage Therapeutics Inc (NASDAQ: SAGE) has reported E.P.S. of $-1.53 for its third fiscal quarter (ending September 30) versus $-3.37 for the same period a year ago — a decline of -55%. For the latest four quarters through September 30, E.P.S. were $-5.58 compared to $-10.98 a year ago — a decline of -49%.
Recent Price Action
Sage Therapeutics Inc (NASDAQ: SAGE) stock closed at $8.48 on 10/29/24 after a slight decline of -0.7%. Moreover, above average trading volume at 139% of normal accompanied the decline. The stock has risen 8.9% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
SAGE is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Sage Therapeutics has a current Value Trend Rating of D (Negative). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Sage Therapeutics has a neutral Appreciation Score of 49 but a very low Power Rating of 15, producing the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment